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Analyzing Tumor Microenvironment and Exploiting its Characteristics 
for Controlling Malignant Solid Tumors and Distant Metastatic Potential 
S. Masunaga 
Research Reactor Institute, Kyoto University 
BACKGROUNDS AND PURPOSES: Human solid 
tumors contain moderately large fractions of quiescent 
(Q) tumor cells that are out of the cell cycle and stop cell 
division, but are viable compared with established ex-
perimental animal tumor cell lines. The presence of Q 
cells is probably due, in part, to hypoxia and the deple-
tion of nutrition in the tumor core, which is another con-
sequence of poor vascular supply. As a result, Q cells are 
viable and clonogenic, but stop cell division. In general, 
radiation and many DNA-damaging chemotherapeutic 
agents kill proliferating (P) tumor cells more efficiently 
than Q tumor cells, resulting in many clonogenic Q cells 
remaining following radiotherapy or chemotherapy. 
Therefore, it is harder to control Q tumor cells than to 
control P tumor cells, and many post-radiotherapy recur-
rent tumors result partly from the regrowth of Q tumor 
cells that could not be killed by radiotherapy. Similarly, 
sufficient doses of drugs cannot be distributed into Q 
tumor cells mainly due to heterogeneous and poor vascu-
larity within solid tumors. Thus, one of the major causes 
of post-chemotherapy recurrent tumors is an insufficient 
dose distribution into the Q cell fractions. 
With regard to boron neutron capture therapy 
(BNCT), with 10B-compounds, boronophenylalanine-10B 
(BPA) increased the sensitivity of the total cells to a 
greater extent than mercaptoundecahydrododecaborate- 
10B (BSH). However, the sensitivity of Q cells treated 
with BPA was lower than that in BSH-treated Q cells. 
The difference in the sensitivity between the total and Q 
cells was greater with 10B-compounds, especially with 
BPA. These findings concerning the difference in sensi-
tivity, including other recovery and reoxygenation fol-
lowing neutron irradiation after 10B-compound admin-
istration were mainly based on the fact that it is difficult 
to deliver a therapeutic amount of 10B from 10B-carriers 
throughout the target tumors, especially into intratumor 
hypoxic cells with low uptake capacities. 
Hypoxia is suggested to enhance metastasis by in-
creasing genetic instability. Acute, but not chronic, hy-
poxia was reported to increase the number of macroscop-
ic metastases in mouse lungs. We recently reported the 
significance of the injection of an acute hypoxia-releasing 
agent, nicotinamide, into tumor-bearing mice as a com-
bined treatment with -ray irradiation in terms of re-
pressing lung metastasis. As the delivered total dose in-
creased with irradiation, the number of macroscopic lung 
metastases decreased reflecting the decrease in the num-
ber of clonogenically viable tumor cells in the primary 
tumor. The metastasis-repressing effect achieved through 
a reduction in the number of clonogenic tumor cells by 
irradiation is much greater than that achieved by releas-
ing tumor cells from acute hypoxia. On the other hand, 
more 10B from BPA than from BSH could be distributed 
into the acute hypoxia-rich total tumor cell population, 
resulting in a greater decrease in the number of highly 
clonogenic P tumor cells with BPA-BNCT than with 
BSH-BNCT and with neutron beam irradiation only. 
BPA-BNCT rather than BSH-BNCT has some potential 
to decrease the number of lung metastases, and an acute 
hypoxia-releasing treatment such as the administration of 
nicotinamide or bevacizumab may be promising for re-
ducing numbers of lung metastases. Consequently, 
BPA-BNCT in combination with nicotinamide and/or 
bevacizumab treatment may show a little more potential 
to reduce the number of metastases. Now, it has been 
elucidated that control of the chronic hypoxia-rich Q cell 
population in the primary solid tumor has the potential to 
impact the control of local tumors as a whole, and that 
control of the acute hypoxia-rich total tumor cell popula-
tion in the primary solid tumor has the potential to impact 
the control of lung metastases. 
The aim of this research project is focused on clari-
fying and analyzing the characteristics of intratumor mi-
croenvironment including hypoxia within malignant solid 
tumors and optimizing cancer therapeutic modalities, 
especially radiotherapy including BNCT in the use of 
newly-developed 10B-carriers based on the revealed find-
ings on intratumor microenvironmental characteristics. 
RESEARCH SUBJECTS: 
The collaborators and allotted research subjects (ARS) 
were organized as follows; 
ARS-1 (26P1-1): Optimization of Radiation Therapy 
Including BNCT in terms of the Effect on a Specific 
Cell Fraction within a Solid Tumor and the Suppressing 
Effect of Distant Metastasis.  (S. Masunaga,et al.) 
ARS-2 (26P1-2): Development of Hypoxic Microenvi-
ronment-Oriented 10B-Carriers. (H. Nagasawa, et al.) 
ARS-3 (26P1-3): Clarification of Mechanism of Ra-
dio-Resistance in Cancer Using Optical Imaging at Tis-
sue Level.  (H. Harada, et al.) 
ARS-4 (26P1-4)*: Analysis of Radiation-Induced 
Cell-Killing Effect in Neutron Capture Reaction.  (R. 
Hirayama, et al.) 
ARS-5 (26P1-5): Transdermal Drug Delivery System 
using Hyaluronan-Conjugated Liposomes as 10B-Carrier 
in Boron Neutron Capture Therapy for Melanoma 
 (S. Kasaoka, et al.) 
ARS-6 (26P1-6): Evaluation of Inclusion Complex of 
Carborane Modified Kojic Acid and Cyclodextrin as 
10B-Carrier in Boron Neutron Capture Therapy.  (T. Na-
gasaki, et al.) 
ARS-7 (26P1-7)*: Molecular Design and Synthesis and 
Functional Evaluation of Anticancer and Molecular Tar-
geting Agents. (Y. Uto, et al.) 
ARS-8 (26P1-8)*: Analyzing Biological Effect of BNCT 
from the Viewpoint of the Changes in Oxygenation Lev-
el. (H. Yasui, et al.) 
ARS-9 (26P1-9): Analyses on the Responsiveness of 
Malignant Tumors to BNCT. (M. Masutani, et al.) 
ARS-10 (26P1-10): Assay for Tumor Cell Survival and 
Tumor Growth Delay through Neutron Capture Reaction 
according to the Changes in Intracellular Concentrations 
within Solid Tumors of Newly- Developed 10B-Carriers. 
(K. Nakai, et al.) 
ARS-11 (26P1-11)*: Antitumor and Metastasis- 
Reppresing Effect of BNCT on Human Breast and 
Pancreatic Cancer Cell Lines. (Y. Matsumoto, et al.) 
 (* Due to the irregular and short operation period of our 
reactor in 2014, the data could not be shown here.) 
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 Significance of Fractionated Thalidomide Administration Combined with γ-Ray 
Irradiation from the Viewpoint of Local Tumor Response and Lung Metastasis 
S. Masunaga1, Y. Sanada1, T. Moriwaki2, K. Tano1, Y. 
Sakurai1, H. Tanaka1, M. Suzuki1, N. Kondo1, M. Na-
rabayashi1, T. Watanabe1, Y. Nakagawa1, A. Maruhashi1 
and K. Ono1 
1Research Reactor Institute, Kyoto University 
2Faculty of Medicine, Kyoto University 
INTRODUCTION:  Thalidomide has been reported to 
induce tumor blood vessel normalization in a mouse 
model [8, 9]. Today, thalidomide is being mainly applied 
as a treatment of certain cancers (multiple myeloma) and 
of a complication of leprosy. Here, using a readily me-
tastasizing murine melanoma cell line, we tried to ana-
lyze the significance of combined treatment with thalid-
omide in radiotherapy with γ-rays in combination with an 
acute hypoxia-releasing agent nicotinamide or mild tem-
perature hyperthermia (MTH), already shown to have the 
potential to release tumor cells from diffusion-limited 
chronic hypoxia [1, 2], in terms of local tumor response 
and lung metastatic potential. Concerning the local tumor 
response, the effect not only on the total (= proliferating 
(P) + quiescent (Q)) tumor cell population but also on the 
Q cell population was evaluated using our original meth-
od for selectively detecting the response of Q cells in 
solid tumors. 
Materials and Methods: B16-BL6 melanoma tu-
mor-bearing C57BL/6 mice were continuously given 
5-bromo-2’-deoxyuridine (BrdU) to label all P cells. The 
tumor-bearing mice then received γ-ray irradiation after 
thalidomide treatment through a single or two consecu-
tive daily intraperitoneal administrations up to a total 
dose of 400 mg/kg in combination with nicotinamide or 
mild MTH. Immediately after the irradiation, cells from 
some tumors were isolated and incubated with a cytoki-
nesis blocker. The responses of the Q and total (= P + Q) 
cell populations were assessed based on the frequency of 
micronuclei using immunofluorescence staining for BrdU. 
In other tumor-bearing mice, 17 days after irradiation, 
macroscopic lung metastases were enumerated. 
Results: Thalidomide raised the sensitivity of the total 
cell population more remarkably than Q cells in both sin-
gle and daily administrations. Daily fractionated admin-
istration of thalidomide elevated the sensitivity of both 
the total and Q cell populations, but especially the total 
cell population, compared with single administration. 
Daily administration, especially combined with MTH, 
decreased the number of lung metastases. 
Discussion: Thalidomide was originally introduced as a 
non-barbiturate hypnotic, but withdrawn from the market 
due to teratogenic effects. However, it has been reintro-
duced and used for a number of immunological and in-
flammatory disorders due to its immunosuppressive and 
anti-angiogenic activity. It inhibits release of tumor ne-
crosis factor from monocytes, and modulates other cyto-
kine action. Thalidomide is racemic, and contains both 
left and right handed isomers in equal amounts: one en-
antiomer is effective against morning sickness, and the 
other is teratogenic. The enantiomers are converted to 
each other at physiological conditions (pH = 7.0) in vivo. 
That is, if a human is given D-thalidomide ((+)- or R-) or 
L-thalidomide ((-)- or S-), both isomers can be found in 
the serum. Hence, administering only one enantiomer 
will not prevent the teratogenic effect in humans. It is 
employed for the acute treatment of the cutaneous mani-
festations of moderate to severe erythema nodosum lep-
rosum (ENL). Available data from in vitro studies and 
preliminary clinical trials suggest that its immunologic 
effects can vary substantially under different conditions, 
but may be related to suppression of excessive tumor 
necrosis factor production and down-modulation of se-
lected cell surface adhesion molecules involved in leu-
kocyte migration [3]. 
As a cancer treatment, thalidomide was shown to in-
hibit basic fibroblast growth factor (bFGF) as well as 
VEGF, two promoters of angiogenesis. It was reported to 
measure the modifications in the tumor environment ear-
ly after an angiogenic treatment of thalidomide, with a 
special focus on possible normalization of the tumor 
vasculature that could be beneficial for radiotherapy [4]. 
Incidentally, angiogenesis also is critical during limb de-
velopment of the foetus. Thalidomide directly inhibits 
angiogenesis induced by bFGF or VEGF in vivo. In 2009, 
it was confirmed that loss of newly formed blood vessels 
is the primary cause of thalidomide teratogenesis, and 
that developing limbs are particularly susceptible because 
of their relatively immature, highly angiogenic vessel 
network. Thus inhibition of angiogenesis is now thought 
to be a main mechanism of its teratogenicity [3,5]. 
Conclusion: It was elucidated that control of the chronic 
hypoxia-rich Q cell population in primary solid tumors 
has the potential to impact the control of local tumors as a 
whole, while control of the acute hypoxia-rich total tumor 
cell population has the potential to impact the control of 
lung metastases. Namely, in conventional radiotherapy, 
daily fractionated administration of thalidomide com-
bined with MTH is thought to have a great potential to 
control both local solid tumors and lung metastases from 
the local tumors [6]. 
REFERENCES: 
[1] S. Masunaga, et al., Int J Hyperthermia 13 (1997) 
401-411. 
[2] S. Masunaga, et al., Clin Exp Metastasis 26 (2009) 
693-700. 
[3] M. E. Franks, et al., Lancet 363 (2004) 1802-1811. 
[4] R. Ansiaux, et al.,Clin Cancer Res 11 (2005) 743-750. 
[5] C. Therapontos, et al., Proc Natl Acad Sci U S A 106 
(2009) 8573-8578. 
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Development of Nucler-targeting Boron Carriers Based on the Chemistry of Direct 
Cell-penetrating Pepducins  
  
A. Isono1, K. Okuda1, T. Hirayama1, S. Masunaga2, and 
H. Nagasawa1  
 
1 Laboratory of Medicinal & Pharmaceutical Chemistry, 
Gifu Pharmaceutical University 
2 Research Reactor Institute, Kyoto University 
 
INTRODUCTION:  For the success of boron neutron 
capture therapy (BNCT), it is essential to selectively de-
liver sufficient amount of 10B atoms to tumor cells. To 
achieve intracellular molecular targeting of drug delivery, 
we focused on the direct cell-penetrating lipopeptides, 
pepducins which were developed as allosteric modulators 
of GPCRs[1]. By the study of fluorescence resonance 
energy transfer (FRET)-based imaging of pepducins, we 
demonstrated that they penetrate directly into cells by 
trans-membrane lipid translocation [2]. Accordingly, we 
envisaged that the pepducin moiety may be exploitable 
for intracellular deliver of membrane impermeable 
molecules such as anionic boron claster, sodium boro-
captate (BSH).  
MOLECULAR DESIGN: As shown in Fig. 1, we des-
igned new hybrid molecules comprising pepducin (Pep) 
as a vehicle, and boron cluster (BS) attached with fluo-
rescent dyes such as 7-hydroxycoumarin (Cou) and 
Hoechst 33342 dye (Hoe) as a cargo; Pep-SS-BS-Cou 
and Pep-SS-BS-Hoe. The cargo is supposed to be re-
leased into cytosol after reductive cleavage of the disul-
fide bond by intracellular glutathione when it is carried 




RESULTS AND DISCUSSION: The lipidated peptides 
were prepared by solid-phase synthesis and then com-
bined with BSH and the corresponding fluorophore 
through an appropriate liker to afford the boron carriers 
(Fig. 2 and 3). We performed live cell imaging experi-
ments using MCF-7 cells with the probes and confocal 
microscopy. By the treatment with Pep-SS-BS-Cou, the 
fluorescence signal was localized on cell-membrane for 
more than 30 min, which suggested that the boron carrier 
was likely to be anchored on the plasma membrane but 
could not be translocated into the cytosol. To evaluate the 
structure activity relationship of the peptide sequence for 
controlling cellular distribution, we synthesized pep-
ducins containing various peptides to conjugate with the 






We also synthesized Pep-SS-BSs by connecting of vari-
ous pepducins to the boron cluster without any fluoro-
phores. To quantify their intracellular boron concentra-
tion, ICP-MS analyses of nuclear and cytoplasmic ex-
tracts will be conducted.  
 
REFERENCES: 
[1] L. Covic et al., Proc. Natl. Acad. Sci. USA., 99 
(2002) 643–648. 
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                Genetic Screening of Upstream Activators of Hypoxia-inducible Factor 1 for the 
                                                 Devrlopment of Novel Anti-cancer Strategies 
  
H. Harada1, S. Masunaga2, M.  
 
1Department of Radiation Oncology and Image-applied 
Therapy, Graduate School of Medicine, Kyoto University. 
2Research Reactor Institute, Kyoto University 
 
INTRODUCTION:  Accumulating evidence has 
shown that hypoxia-inducible factor 1 (HIF-1) plays crit-
ical roles in distant tumor metastases at multiple steps [1] 
and eventually causes death among cancer patients. Clin-
ical studies have demonstrated consistent data that HIF-1 
could be used as an adverse prognostic factor for not only 
local tumor recurrence but also distant tumor metastasis 
in cancer patients. These findings justify targeting HIF-1 
for cancer therapies.   
HIF-1, a heterodimeric transcription factor composed of 
an -subunit (HIF-1) and a -subunit (HIF-1), is 
known to become activate mainly through the stabiliza-
tion of HIF-1 protein. Under normoxic conditions, 
prolyl-4-hydroxylases (PHDs) hydroxylate proline resi-
dues, P402 and P564, in the oxygen-dependent degrada-
tion domain (ODD domain) of HIF-1 in an oxy-
gen-dependent manner. The hydroxylations trigger 
polyubiquitilation and subsequent proteasomal degrada-
tion of HIF-1. On the contrary, HIF-1 becomes active 
under hypoxic conditions because of the inactivation of 
the hydroxylases, and then, interacts with its binding 
partner, HIF-1. Resultant heterodimer, HIF-1, binds to 
its cognate enhancer sequence, the hypoxia-responsive 
element (HRE), and induces transcriptions of various 
genes related to the escape from hypoxia (invasion and 
metastasis of cancer cells) as well as the improvement of 
oxygen-availability (angiogenesis) and adaptation of cel-
lular metabolism to hypoxia (metabolic reprogramming).  
In order to explore novel genes which are responsible 
for the HIF-1-mediated tumor metastasis, we recently 
established a new genetic screening method [2] and 
found that overexpression of ubiquitin C-terminal hydro-
lase L1 (UCHL1) is responsible for the activation of 
HIF-1. In the present study, we analyzed both the molec-
ular mechanisms underlying the UCHL1-mediated acti-
vation of HIF-1 and the involvement of UCHL1-HIF-1 
axis in distant tumor metastases.   
 
EXPERIMENTS & RESULTS:  We established stable 
transfectants of HeLa cells with the UCHL1 expression 
vector (HeLa/UCHL1) or its empty vector (HeLa/EV) [3]. 
We found that aberrant expression of UCH-L1 in cancer 
cells abrogated von Hippel-Lindau-mediated ubiquitina-
tion of HIF-1, leading to the stabilization of HIF-1 and 
subsequent activation of HIF-1 (Fig. 1) [3].  
 A murine model of pulmonary metastasis demonstrated 
that the forced expression of UCH-L1 facilitated tumor 
metastases in a HIF-1-dependent manner (Fig. 2) [3].  
 
 On the other hand, silencing of the aberrantly expressed 
UCH-L1 suppressed the metastatic tumor formation by 
inactivating HIF-1[3].  
Moreover, we revealed that UCH-L1 expression levels 
were associated with poor prognosis of patients with 
breast and lung cancers (Fig. 3) [3]. 
 
  
DISCUSSIONS:  Together, these results demonstrate 
that UCH-L1 functions in distant tumor metastasis as a 
deubiquitinating enzyme for HIF-1, and thus, justify 
exploiting it as a prognostic marker and therapeutic target 
for individualization of cancer therapy. 
 
REFERENCES (papers published from our lab): 
[1] Zhao T et al. Sci Rep. 4:3793. 2014. 
[2] Zeng L et al. Oncogene. in press. 







Quantitative Detection of Metastasized B16BL6 Cells in Lung by Using 
TaqMan RT-PCR Assay 
  
T. Nagasaki, J. Kawaguchi, R. Kawasaki, M. Sakuramoto, 
M. Kirihata1, Y. Hattori1, S. Masunaga2 and Y. Sakurai2 
 
Graduate School of Engineering, Osaka City University 
1 BNCT Research Center, Osaka Prefecture University, 
2Research Reactor Institute, Kyoto University 
 
 
INTRODUCTION:   Although melanoma boron neu-
tron capture therapy (BNCT) with L-10B-p-boronophenyl 
alanine has been treated for melanoma patient, the en-
hancement of 10B accumulation in melanoma cells would 
lead to improved efficacy of malignant melanoma BNCT. 
Recently, we have evaluated the inclusion complex of 
kojic acid-appended carborane (CKA) with hydroxypro-
pyl- -cyclodextrin (HP- -CD) as a novel boron agent for 
BNCT toward melanoma. CKA/HP- -CD complex 
showed melanoma cells selectivity, unique nuclear local-
ization, and high tumor-suppression effect on BNCT to-
ward melanoma-bearing mice. Furthermore, 
CKA/HP- -CD complex was found to be the potent in-
hibitor of hypoxia-induced HIF-1  and to have a strong 
effect on tumor metastasis [1]. Herein, in order to evalu-
ate quantitatively metastasis-suppression, TaqMan 
RT-PCR assay of melanoma gene GP100 was carried out 
toward melanoma B16BL6 cells metastasis from thigh 










EXPERIMENTS:  B16BL6 cells (2.5 1012 cells) were 
implanted into thigh subcutaneous. Mice were euthanized 
and lung and spleen were isolated and snap frozen in liq-
uid nitrogen before being stored at - Total RNA was 
extracted using NucleoSpinRNA Kit (Takara). Total 
RNA concentration and purity were measured using 
NanoDrop 2000c Spectrometer (Thermo Scientific). 
Subsequently, cDNA synthesis was performed by using 
PrimeScriptTM RT reagent Kit (Perfect Real Time) 
(Takara). Quantitative real time polymerase chain reac-
tion (Q-PCR) was performed according to the manufac-
(Roche) and Q-PCR was run in a STRAGENE Mx3000P 
using the following program: 
. Primers and probe were 
 AGC ACC TGG AAC CAC 
ATC TA GAG GGC GTT 
TGT GTA GT 3 probe: 5'Hex-CAC TAC AAA 
AGT TGT GGG TAC TAC ACC TG-BHQ-1-3'.  
 
 
RESULTS AND DISCUSSION:  GP100 is highly 
expressed in melanoma B16BL6 cells, but not to any 
substantial degree in normal tissues. GP100 expression 
exceeded background levels when at least 5 103 B16BL6 
cells are contained in metastasized tissue. In order to 
quntify the increase of metastasized B16BL6 cells, lungs 
were collected 1, 3, 7, or 14 days post tumor implantation. 
On  day 7 increase of GP100 expression reached a level 
of about 100 times the lowest point (Fig. 1).  
  TaqMan RT-PCR Assay toward GP100 is potent to 
estimate quantitatively the metastasis of melanoma cells 
to lung. The quantitative evaluation of metasta-
sis-suppression effect of CKA/HP- -CD complex is pro-




[1] K. Shimizu et al., Bioorg. Med. Chem. Lett., 20 
(2010) 1453-1456. 




Fig.1  Relative mRNA expression of melanoma gene 
GP100 in lungs. 
Structure of CKA/HP- -CD 
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 Response of Tumor Cells to BNCT 
  
S. Imamichi1, T. Itoh1,2, S. Kikuhara1,2, H. Fujimori1, A. 
Sato3, T. Hirai1,4, S. Masunaga5 and M. Masutani1,6 
 
1Division of Chemotherapy and Clinical Research, Na-
tional Cancer Center Research Institute, 2Faculty of In-
dustrial Science and Technology, Tokyo University of 
Science, 3Faculty of Pharmaceutical Sciences, Tokyo 
University of Science, 4Department of Radiation Oncol-
ogy, Juntendo University Faculty of Medicine, 5 Research 
Reactor Institute, Kyoto University, 6Department of 
Frontier Life Sciences, Nagasaki University Graduate 
School of Biomedical Sciences 
 
INTRODUCTION: Tumors are consisted of hetero-
genous populations of cells, including hypoxic cells, 
cancer stem cells and differentiating cells. These popula-
tions affect the consequence of the boron neutron capture 
therapy (BNCT) [1]. Boron neutron capture reaction 
(BNCR) causes extensive DNA double strand breaks and 
micronuclei formation has been used to estimate the level 
of DNA damage induced by BNCR [2].  In rat xenograft 
model, BNCR caused the up-regulation of H2AX and 
HMGB1, then induction of poly(ADP-ribose) [3]. The 
cell death process and the factors affecting tumor cell 
killing, side effects and effectiveness of BNCT are not 
fully understood. To elucidate the cell death process after 
BNCR, we have taken approaches of comprehensive 
analysis of the tumor cells by using transcriptome and 
proteome analysis.  
 
EXPERIMENTS:  Human oral squamous cancer SAS 
cells [1] was used for the comprehensive analysis with 
transcriptome and proteome analysis. 
10B-boronophenylalanine (10B-BPA)-fructose solution 
was prepared as described previously [4]. SAS cell was 
suspended and incubated 2 h with or without 25 ppm of 
10B-BPA as previously reported [3]. After neutron-beam 
irradiation operated at 1 MW, cells were inoculated for 
colony formation, RNA and protein preparation. To ana-
lyze the early response of cancer cells, RNA and protein 
were prepared 6 and 24 hrs after irradiation at the sup-
posal doses of 4 Gy-eq and 24 Gy-eq conditions.  
For mouse xenograft model, male BALB/c-nu/nu  
mice were used and SAS cells were injected subcutane-
ously into left legs of the mice. 10B-BPA at the dose of 
250 mg/kg bodyweight was intraperitoneally injected 1 h 
before irradiation operated at 1 MW. Tumors, tissues, and 
blood were sampled for the analysis of early responses 
after irradiation. The animal studies were performed in 
accordance with the relevant laws and institutional guide-
lines of KUR and NCC.  10B concentration was meas-
ured by prompt-gamma ray analysis (PGA). Thermal 
neutron fluence was measured with gold foils activation 
analysis. Gamma-ray dose was measured with thermalu-
minescence dosimeter. These physical radiation doses 
were measured with the kind help of Drs. Yoshinori Sa-
kurai and Hiroki Tanaka of KUR.  
 
RESULTS:   
The measured 
results of total 
physical dose, 
neutron and 
gamma ray dose 
were shown in 
Fig. 1 and con-
firmed that the 
dose estimation 
was in the ex-
pected range. 
Twenty-four hrs 
after 24 Gy-eq 
irradiation, SAS 
cells showed the 
cleavage of 
PARP1, caspase-9 and caspase-3, suggesting that apopto-
sis started to occur. Meanwhile, the low levels of necrotic 
cleavage pattern of PARP1 were also observed, implying 
that necrotic cell death is also involved after BNCR. The 
isolated RNA 6 and 24 hrs after irradiation was evaluated 
by electrophoresis and RT-PCR. As shown in Fig. 2, the 
expression levels of PARP1 and GUSB were not different 
among the irradiation conditions, confirming the quality 
of RNA. In the microarray analysis, we found that the 
expression of the genes related to cell death, transcription, 
and inflammatory and immune responses was augmented 
after BNCR and the further evaluation is ongoing.  
By proteome analysis, proteins involved in the vesicle 
regulation, mRNA processing, transcription were ob-
served with 
changes after 
BNCR and being 
studied further. 
The observation 
suggests that dynamic changes in cellular responses could 
be induced after BNCR reaction at an early phase. SAS 
xenograft model in nude mice was also set up, and the 
boron concentration in the blood and tissues was meas-
ured. Using the experimental system, the genes and pro-




[1] Masunaga et al, Jpn. J. Cancer Res., 93(12) (2002) 
1366-77.  
[2] Kinashi et al, Radiat. Oncol., 5;6 (2011) 106.  
[3] M. Masutani et al, Appl. Radiat Isot.88 (2014) 104-8.  
[4] Yoshino et al, Strahlen. Onkol., 165: (1998) 127-12
Fig. 1. The physical dose measurement.  
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Additive effect of Gadolinium to cell survival analysis  
for neutron capture therapy 
  
K. Nakai1, F. Yoshida1, T. Kurita1, Y. Yamamoto1, M. 
Shirakawa2, T. Yamamoto1, H. Tanaka3, Y. Sakurai3, S. 
Masunaga3 
 
1Department of Nueurosurgery ,Faculty of Medicine, 
University of Tsukuba 
2Department of Pharmaceutical Sciences,International 
University of Health and Welfare 
3Research Reactor Institute, Kyoto University 
 
 
INTRODUCTION:  In neutron capture therapy; the 
therapeutic effect of a boron compound is based on alpha 
particle production in a 10B(n, α) 7Li reaction, while a 
gadolinium compound effect is based on producing 
gamma rays derived from a 157Gd(n, γ) reaction[1,2]. 
Gadolinium containing agents has been used for contrast 
enhance of MRI scan, and are commercially available as 
pharmaceutical products. 
 If gadolinium is administered simultaneously with bo-
ron and irradiated with neutrons, it might become a 
source of additional local gamma rays, which correspond 
with recent BNCT clinical trial protocol for glioblastoma. 
We analyzed the additive effect of gadolinium on boron 
based neutron capture reaction. 
 
Materials and Methods:  
Boron and Gadolinium compounds 
p-boronophenylalanine (BPA) was obtained from Inter-
pharma Praha (Praha, Czech Republic). Gd-DTPA 
(Magnevist) was purchased from Shering (Berlin, Ger-
many). BPA and fructose ware dissolved and prepared as 
previously described. Briefly, BPA was converted to 
BPA-fructose complex by mixing BPA and fructose in 
NaOH. The pH was adjusted to 7.4 with HCl. Dissolution 
solvent for Gd-DTPA was cell culture medium. 
Cell lines; C6 rat glioma cell lines and V79 Chinese 
hamster cell lines were maintained in Eagle’s Minimum 
Essential Medium (MEM; Sigma-Aldrich), supplemented 
with 10% fetal bovine serum. 
Colony Formation Assay ;V79 cells and C6 cells after 
exposition with the compounds were irradiated with neu-
tron mixed beam for 90 min at the Kyoto University Re-
search Reactor (KUR). We use the combination of BPA 
(0, 10, 20, 40 Bu µµg/mL) and Gd-DTPA (0, 0.5, 5, 10 
Gdµg/mL) with 104 of cells of each line. The number of 
cells was sufficient to produce 20-100 colonies at each 
boron concentration. After 7days of incubation, the plates 
were stained with 0.25 % methylene blue in 90 % ethanol. 
Colonies of more than 50 cells were counted. 
 
 
RESULTS:  As shown in Fig. 1, Radiation-related 
damage significantly increased with the increase of gado-
linium concentration. When 5 ppm of Gd-DTPA was 
added to 40 ppm of BPA in C6 cells, the additive effect 
was obtaine. In radiosensitive V79 cells the survival frac-
tion dramatically decreased after irradiation and was 
lower than 10% at boron concentration of 40ppm. 
 
 
Fig. 1.  Influence of Gd on BNCT in C6 (upper), V79 
(lower) cell lines. The symbols ◆ show the control 
(BPA only); ■ show the result of additional 0.5 ppm of 
Gd; ▲ show the result of additional 5 ppm of Gd and 
×  show the result of additional 10 ppm of Gd.  
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